NCT02934269View on ClinicalTrials.gov

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

August 15, 2017

Study Completion Date

August 15, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

Placebo

DRUG

CC-90006

Trial Locations (1)

78744

PPD Phase 1 Unit, Austin

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02934269 - A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects | Biotech Hunter | Biotech Hunter